KALA - Kala Pharmaceuticals Has Good Short- And Long-Term Prospects
- Kala Pharmaceuticals’ Eysuvis, a corticosteroid-based drug, was approved for both signs and symptoms of dry eye disease last year and sale calls began on Jan 4th 2021.
- The market uptake of Eysuvis has been good so far and will likely speed up further after more insurers come on board.
- More insurers are likely to be favoring Eysuvis because of its quick response and relatively lower cost compared to other dry eye drugs on the market.
- In the short term, Kala Pharmaceuticals will likely beat Q1 2021 revenue estimate. In the long term, the company is in a good position to rapidly expand the sales of both drugs.
For further details see:
Kala Pharmaceuticals Has Good Short- And Long-Term Prospects